{"id":539301,"date":"2021-04-19T18:24:01","date_gmt":"2021-04-19T18:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=539301"},"modified":"2021-04-19T18:24:01","modified_gmt":"2021-04-19T18:24:01","slug":"narcolepsy-pipeline-assessment-key-companies-and-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/narcolepsy-pipeline-assessment-key-companies-and-emerging-drugs_539301.html","title":{"rendered":"Narcolepsy Pipeline Assessment, Key Companies, And Emerging Drugs"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Narcolepsy Pipeline Assessment, Key Companies, And Emerging Drugs\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Narcolepsy Pipeline Assessment, Key Companies, And Emerging Drugs\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Narcolepsy Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Narcolepsy Market. <\/div>\n<p style=\"text-align: justify;\">The <strong>Narcolepsy Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the Narcolepsy pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <strong>Narcolepsy collaborations<\/strong>, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at:&nbsp;<\/strong><br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/narcolepsy-pipeline-insight\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/narcolepsy-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">As of now, there is no cure for Narcolepsy, however, with lifestyle modification and medications some of the symptoms of Narcolepsy can be managed. Medications used for Narcolepsy include Modafinil, Amphetamine-like stimulants, Antidepressants, Sodium oxybate and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key Narcolepsy Companies in the market include: <\/strong><br \/>Addrenex Pharmaceuticals<br \/>Graymark Healthcare<br \/>Bioprojet Pharma<br \/>Teva Pharmaceutical Industries<br \/>Jazz Pharmaceuticals <br \/><strong>And many others.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Narcolepsy Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/aa303d6040380c2ecde0f2794b397d39.jpg\" alt=\"Narcolepsy Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/narcolepsy-pipeline-insight\" target=\"_blank\"><strong>Narcolepsy Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Narcolepsy<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Narcolepsy Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Narcolepsy key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Narcolepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Narcolepsy market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The <strong>Narcolepsy Pipeline Report<\/strong> provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Narcolepsy across the complete product development cycle, including all clinical and non-clinical stages.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It comprises detailed profiles of <strong>Narcolepsy therapeutic products<\/strong> with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed research and development progress and <strong>clinical trial of Narcolepsy<\/strong>, results wherever available, are also included in the pipeline study.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage of dormant and discontinued pipeline projects along with the reasons if available across Narcolepsy.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of <strong>novel therapeutics for Narcolepsy<\/strong>.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the coming years, the Narcolepsy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The companies and academics are working to assess challenges and seek opportunities that could influence <strong>Narcolepsy Research &amp; Development<\/strong>. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A detailed portfolio of major pharma players who are involved in fueling the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/narcolepsy-pipeline-insight\" target=\"_blank\"><strong>Narcolepsy treatment market<\/strong><\/a>. Several potential therapies for Narcolepsy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Narcolepsy market size in the coming years.&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Our in-depth analysis of the <strong>Narcolepsy pipeline assets<\/strong> (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Narcolepsy&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Narcolepsy Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Narcolepsy &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Narcolepsy Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Narcolepsy Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Narcolepsy Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Narcolepsy Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Narcolepsy Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Narcolepsy Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Narcolepsy Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Narcolepsy Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Narcolepsy Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Latest Reports By DelveInsight<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/narcolepsy-market\">Narcolepsy Market Insight<br \/><\/a><\/strong>DelveInsight&#8217;s &#8220;Narcolepsy Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Narcolepsy market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/narcolepsy-epidemiology-forecast\">Narcolepsy Epidemiology Forecast<br \/><\/a><\/strong>DelveInsight&#8217;s Narcolepsy &#8211; Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Narcolepsy in the 7MM.<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><br \/>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=narcolepsy-pipeline-assessment-key-companies-and-emerging-drugs\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=narcolepsy-pipeline-assessment-key-companies-and-emerging-drugs\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP &#8220;Narcolepsy Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Narcolepsy Market. The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the Narcolepsy pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/narcolepsy-pipeline-assessment-key-companies-and-emerging-drugs_539301.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-539301","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=539301"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539301\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=539301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=539301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=539301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}